Administration & Faculty

Fawzy A. Elbarbry, PhD

Assistant Professor

503-352-7356
fawzy.elbarbry@pacificu.edu

 

Education

2006 Postdoctoral Fellow

Dept. of Medicine,

University of Saskatchewan, Canada

2006 Doctor of Philosophy,

Pharmacy, Drug Metabolism,

and Pharmacokinetics,

University of Saskatchewan, Canada

2002 Master of Science,

Analytical Chemistry,

College of Pharmacy,

University of Tanta, Egypt

1995 Postgraduate Diploma,

Analytical Chemistry,

College of Pharmacy,

University of Tanta, Egypt

1993 Bachelor of Pharmaceutical Sciences,

College of Pharmacy,

University of Tanta, Egypt

 

Areas of Research & Specialization

My research interests revolve around minimizing toxicity and/or drug interactions of xenobiotics through better understanding of their effect on drug metabolizing enzymes (DME), especially Cytochrome P450 (CYP) enzymes.  Although CYP enzymes normally generate metabolites with diminished biological activity, there are numerous examples where these enzymes mediate the formation of reactive intermediates from chemically inert agents.  These reactive metabolites play a key step in initiating cellular damage and cancers.  Modification of the activity or expression level of CYP enzymes through exposure to environmental toxins, drugs, or even herbal remedies could potentially affect the clinical outcome of concomitantly-administered drugs.  My research interest focuses on identifying the role of CYP enzymes in toxicity induced by drugs, herbal remedies and environmental toxins.  Along with the mission of Pacific University and the School of Pharmacy, the outcome of this research will be utilized to advance the level of pharmaceutical care within the community and improve health care literacy among patients.

 

Publications

Book Chapters

Elbarbry F.  Introduction to Toxicology. In: Karimi R, editor.  Biomedical and Pharmaceutical Sciences with Patient Care Correlations. 2012 (in progress)

Elbarbry F and Karimi R. Introduction to Pharmacokinetics. In: Karimi R, editor.  Biomedical and Pharmaceutical Sciences with Patient Care Correlations. 2012 (in progress)

 

Journal Articles

Ahmed H, Elbarbry F, Clark B.  Mixed Micellar Electrokinetic Chromatographic Analysis of Colistin, a Polypeptide Antibiotic, Using Laser-Induced Fluorescence Detection.  AJAC. 3:233-241. 2012

Elbarbry F, Ragheb A, Marfleet T, and Shoker A.  Modulation of Hepatic Drug Metabolizing Enzymes by Dietary Doses of Thymoquinone in Female New Zealand White RabbitsPhytotherapy Research. 2012

Karimi R,  Elbarbry F, Fortner J. Integrative Student Learning: An Effective Team Learning Activity in a Learner-Centered Paradigm.  Innovations in Pharmacy. 2(4):1-16. 2011

Elbarbry F and Elrody N. Potential Health Benefits of Sulforaphane: A Review of the Experimental, Clinical and Epidemiological Evidences and Underlying Mechanisms. JMPR. 5(4): 473-484. 2011

Elbarbry F, Chibbar R, Marfleet T, and Shoker A.  Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity. Xenobiotica. 40(11):772-81. 2011

Karimi R, Arendt C, Elbarbry F, Roberts S.  Learning bridge: curricular integration of didactic and experiential education. AJPE. 74(3): article 48. 2010

Ragheb A, Attia A, Elbarbry F, Prasad K, Shoker A. Attenuated combined action of cyclosporine a and hyperlipidemia on atherogenesis in rabbits by thymoquinone. Evid Based Complement Alternat. Med.  2010

Elbarbry F, Attia A, Shoker A.  Validation of a new HPLC method for determination of midazolam and its metabolites: application to determine its pharmacokinetics in human and measure hepatic CYP3A activity in rabbitsJ Pharm Biomed Anal.  50(5):987-93. 2009

Ragheb A, Attia A, Elbarbry F, Shoker A. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. SJKDT. 20(5): 741-752. 2009

Elbarbry F and Alcorn J. Ontogeny of glutathione and glutathione-related antioxidant enzymes in rat liver. Research in Veterinary Sciences. 87(2):242-244. 2009

Ragheb A, Elbarbry F, Prasad K, Mohammed A, Shoker A.  Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. Int. J. Angiol. 17(4):186-192. 2008

Elbarbry F, Marfleet T, and Shoker A.  Drug-drug interactions with immunosuppressive agents: review of the in vitro functional assays and role of cytochrome P450 enzymes. Transplantation. 85(9), 1222-1229. 2008

Elbarbry F and Shoker A. Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application. J Chromatogr. B. 859(2):276-81. 2007

Elbarbry F and Shoker A.   Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clinical Biochemistry. 40(11):752-64. 2007

Elbarbry F, McNamara P, and Alcorn J.  Ontogeny of hepatic CYP1A2 and CYP2E1 expression in rat. J Biochem. Mol Toxicol. 21(1):41-50. 2007

Elbarbry F, Eldawy M, Mabrouk M. Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. J AOAC Int. 90(1): 94-101. 2007

Alcorn J, Elbarbry F, and McNamara P.  Evaluation of the assumptions of an ontogeny model of rat hepatic cytochrome P450 activity. Drug Metabolism and Disposition. 35(12):2225-31. 2007

Elbarbry F and Shoker A.  Simple high performance liquid chromatographic assay for mycophenolic acid in renal transplant patientsJ Pharm. Biomed Anal. 43(2): 788-92. 2007

Elbarbry F, Wilby K, and Alcorn J. Validation of a HPLC method for the determination of p-nitrophenol hydroxylase activity in rat hepatic microsomesJ Chromatogr. B. 834 (1-2): 199-203. 2006

Elbarbry F and Alcorn J. Maturation of Cytochrome P450 2E1 and Glutathione-S-Transferases, Pharmacokinetic Model Validation, J Pharm. Pharmaceutical Sci., 7(2): 284-302. 2004

Eldawy M, Mabrouk M, and El-barbary F. Determination of chlorpheniramine maleate and tincture ipecac in dosage form by liquid chromatography with ultraviolet detection. J AOAC Int. 86 (4): 675-80. 2003

Eldawy M, Mabrouk M, and El-barbary FLiquid chromatographic determination of fluoxetine.  J Pharm Biomed Anal. 30 (3), 561-71. 2002

 

 

Back to Administration & Faculty Listing